The European Cannabis Report: 7th Edition

2021 was another huge year for the liberalisation and mainstreaming of cannabis in Europe. Legislation, regulations and market developments continued to evolve for the better. Many countries continued to improve their medical cannabis access schemes, and Prohibition Partners estimates that €354 million worth of unlicensed medical cannabis will be sold in Europe in 2022, and this could reach to €2.3 billion in 2026. CBD products are continuing their path towards recognition as fully-legal consumer packaged goods (CPGs). As of 2022, several novel foods applications for CBD have been validated by the European Commission. But, the story which is drawing most international attention is the upcoming liberalisation of adult-use cannabis in Europe, with the ruling coalition of Germany promising full legalisation and commercialisation of adult-use cannabis in this legislative term. Legal sales are set to start in Switzerland by the end of 2022 followed shortly by those in the Netherlands.

• Market Sizing
• · Unlicensed Medical Cannabis Sales in Europe
• · Projected Sales of Adult Use Cannabis in Europe
• · CBD Sales in Europe
• · Country Focus
• Expert Interviews
• · Benedikt Sons, Cansativa Group
• · Jakob Sons, Cansativa Group
• · Timo Bongartz, Fluence EMEA
• · Dr Anne Schlag, Project Twenty21
• · Bek Muslimov & Nikolay Tretiyakov, Leafy Tunnel
• · Denise Fatischek, Tilray
• CBD
• · Fragmented European Markets
• · CBD Legislation in Europe
• · CBD as a Cosmetic
• · CBD as a Medicine
• · Ingestible CBD
• · CBD Flowers
• Trends
• · Medical Cannabis
• · Pilot Trials
• · Supply Chain
• · Product Shortages in Europe
• · Countries Allowing Cultivation in Europe
• · Patients and Products
• · Expert Interviews
• Country Focus
• · Germany
• · Italy
• · The Netherlands
• · Poland
• · United Kingdom
• · Switzerland
• · Czechia

• · Prohibition Partners estimates that, in 2022, 100,000 additional patients will be able to access medical cannabis products in Europe for the first time, bringing the total number of patients to 341,595
• · Prohibition Partners predicts that sales of adult-use cannabis in Europe could reach €1.5 billion by 2026, but this forecast is dependent on swift progress and full implementation of adult-use legalisation in Germany.
• · Prohibition Partners project €357 million of unlicensed cannabis medicines will be sold in Europe in 2022, growing to €2.3 billion by 2026.
• · The German medical market continues to grow steadily, with a 43% increase in sales of cannabis to pharmacies in 2021 (majority sold to patients on private prescriptions).
• · In England, the number of unlicensed medical cannabis products dispensed for private prescription grew by 425% to an annual 23,466 products.
• · The UK market could constitute about a quarter of the European medical cannabis market by 2026, or €544 million.
• · North American cannabis operators remain heavily invested in Europe, with hundreds of millions of euros worth of assets on the continent.
• · Operators in at least 15 European countries are now cultivating medical cannabis for commercial purposes.